Compounds and method for blocking transmission of malarial parasite

US10988472B2 · kind B2 · utility

Assignees

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US
• Loyola University of Chicago · US

Inventors

• Wenwei Huang · Rockville, US
• Hao Li · Brookline, US
• Wei Sun · Daxi District, TW
• Xiuli Huang · Potomac, US
• Paresma R. Patel · Rockville, US
• Hangmao Sun · Germantown, US
• Wei Zheng · Rockville, US
• Xiao Lu · Rockville, US
• Philip E. Sanderson · Bethesda, US
• Myunghoon Kim · Olympia, US
• Meghan J. Orr · Chicago, US
• Gregory J. Tawa · Doylestown, US
• Kim C. Williamson · Rockville, US

Key dates

• Filing date: Oct 13, 2017
• Grant date: Apr 27, 2021
• Expiry date: Oct 13, 2037

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Disclosed are compounds of formula (I) and formula (II): (I) (II) wherein R1, R2, A, and B are as defined herein. Also disclosed is a method of blocking transmission of a Plasmodium parasite and a method of treating or preventing malaria comprising administering to an animal an effective amount of a first compound of formula (I) or (II) either alone or in combination with a second compound selected from elesclomol, NSC174938, NVP-AUY922, Maduramicin, Narasin, Alvespimycin, Omacetaxine, Thiram, Zinc pyrithione, Phanquinone, Bortezomib, Salinomycin sodium, Monensin sodium, Dipyrithione, Dicyclopentamethylene-thiuram disulfide, YM155, Withaferin A, Adriamycin, Romidepsin, AZD-1152-HQPA, CAY10581, Plicamycin, CUDC-101, Auranofin, Trametinib, GSK-458, Afatinib, and Panobinostat.